Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.

Radtke JP, Giganti F, Wiesenfarth M, Stabile A, Marenco J, Orczyk C, Kasivisvanathan V, Nyarangi-Dix JN, Schütz V, Dieffenbacher S, Görtz M, Stenzinger A, Roth W, Freeman A, Punwani S, Bonekamp D, Schlemmer HP, Hohenfellner M, Emberton M, Moore CM.

PLoS One. 2019 Aug 26;14(8):e0221350. doi: 10.1371/journal.pone.0221350. eCollection 2019.

2.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
3.

Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.

Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C.

Eur Urol. 2019 Feb;75(2):310-318. doi: 10.1016/j.eururo.2018.07.031. Epub 2018 Aug 3.

PMID:
30082150
4.

Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.

Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ.

Eur Urol Focus. 2018 Mar;4(2):228-234. doi: 10.1016/j.euf.2016.07.007. Epub 2016 Aug 4.

PMID:
28753781
5.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

6.

Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population.

Chiu PK, Roobol MJ, Nieboer D, Teoh JY, Yuen SK, Hou SM, Yiu MK, Ng CF.

Prostate Cancer Prostatic Dis. 2017 Mar;20(1):99-104. doi: 10.1038/pcan.2016.57. Epub 2016 Nov 29.

PMID:
27897172
7.

Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T.

BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5.

8.

How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?

Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.

Int J Clin Oncol. 2019 Aug 31. doi: 10.1007/s10147-019-01524-9. [Epub ahead of print]

PMID:
31473884
9.

European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.

Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.

BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.

10.

Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.

PMID:
22104592
11.

The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.

12.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.

Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.

13.

Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.

Bjurlin MA, Renson A, Rais-Bahrami S, Truong M, Rosenkrantz AB, Huang R, Taneja SS.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30122-6. doi: 10.1016/j.euf.2018.05.005. [Epub ahead of print]

PMID:
29802053
14.

Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.

Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH.

Eur Urol. 2017 Jul;72(1):45-51. doi: 10.1016/j.eururo.2017.01.033. Epub 2017 Feb 2.

PMID:
28162815
15.

Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.

Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TR, Weidemann J, Renckly S, Kuczyk MA, Wacker F, Peters I.

World J Urol. 2015 Nov;33(11):1707-14. doi: 10.1007/s00345-015-1525-4. Epub 2015 Mar 14.

PMID:
25774003
16.

Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.

Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW.

Eur Urol Focus. 2015 Sep;1(2):185-190. doi: 10.1016/j.euf.2015.06.004. Epub 2015 Jun 23.

PMID:
28723432
17.

Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.

van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ.

Eur J Cancer. 2012 Aug;48(12):1809-15. doi: 10.1016/j.ejca.2012.02.002. Epub 2012 Mar 7.

PMID:
22406050
18.

Validating the European randomised study for screening of prostate cancer (ERSPC) risk calculator in a contemporary South African cohort.

Kowlessur B, Phull M, Patel B, Henry M, Lazarus J.

World J Urol. 2019 Sep 14. doi: 10.1007/s00345-019-02947-9. [Epub ahead of print]

PMID:
31522234
19.

Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.

Jeong CW, Lee S, Jung JW, Lee BK, Jeong SJ, Hong SK, Byun SS, Lee SE.

PLoS One. 2014 Apr 7;9(4):e94441. doi: 10.1371/journal.pone.0094441. eCollection 2014.

20.

Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up.

De Visschere P, Pattyn E, Ost P, Claeys T, Lumen N, Villeirs G.

J Belg Soc Radiol. 2016 Nov 24;100(1):108. doi: 10.5334/jbr-btr.1147.

Supplemental Content

Support Center